InvestorsHub Logo
Followers 33
Posts 2049
Boards Moderated 0
Alias Born 11/06/2011

Re: Lady_luck post# 30622

Thursday, 12/03/2020 11:37:37 AM

Thursday, December 03, 2020 11:37:37 AM

Post# of 34624
As much as it might seem that we would be better off with Wilson I 100% disagree. We'd still be fumbling around with the TPIV trials and god knows how many more reverse splits we'd have to go through. The only reason the merger with Marker originally happened was because of Peter. Without Peter we would have no MultiTAA and right now that has more promise than the peptide vaccines ever will. MultiTAA is the only reason the funding came in at the time of the merger and the financing deal with Aspire transpired. No way TPIV and Wilson would have been able to generate that kind of funding.

The delays were definitely frustrating but 90% of it was beyond the company's control. I know everyone wants to put the blame somewhere and the logical choice is the CEO but I fully believe the company would be no further along with any different CEO. It's been said multiple times since the merger that the main focus would be the Phase II AML trial. It was supposed to start by the end of 2019 originally but then the reagent issue popped up. There was no way this could have been foreseen by anyone at the company and as far as I'm concerned it should have been a non issue. The FDA saw otherwise. That pushed the start of the trial out to early 2020 and we all know what happened then. Covid threw a wrench into a lot of plans for many companies. Can't blame the company or CEO for that.

A little more communication would be nice. That's the one place I would put some blame on Peter but the unfortunate reality is that with all the unexpected delays there hasn't been a whole lot of news to share. It is what it is and there isn't a whole lot anyone can do about it. As far as the many opportunities he just flushed down the toilet I'm failing to come up with any. Can you please enlighten me on these?

Friends don't let friends place market orders

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News